JP2019526582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526582A5 JP2019526582A5 JP2019512205A JP2019512205A JP2019526582A5 JP 2019526582 A5 JP2019526582 A5 JP 2019526582A5 JP 2019512205 A JP2019512205 A JP 2019512205A JP 2019512205 A JP2019512205 A JP 2019512205A JP 2019526582 A5 JP2019526582 A5 JP 2019526582A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- independently
- disorder
- substituted
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 94
- 150000001875 compounds Chemical class 0.000 claims description 79
- 150000003839 salts Chemical class 0.000 claims description 68
- 208000035475 disorder Diseases 0.000 claims description 55
- 201000010099 disease Diseases 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 206010012289 Dementia Diseases 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 230000002685 pulmonary effect Effects 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 206010020772 Hypertension Diseases 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 208000020016 psychiatric disease Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 208000011117 substance-related disease Diseases 0.000 claims description 9
- 230000000472 traumatic effect Effects 0.000 claims description 9
- 206010011878 Deafness Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 208000029560 autism spectrum disease Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 230000010370 hearing loss Effects 0.000 claims description 8
- 231100000888 hearing loss Toxicity 0.000 claims description 8
- 208000016354 hearing loss disease Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 7
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 208000029028 brain injury Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 229960004502 levodopa Drugs 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 6
- 208000027534 Emotional disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 230000000414 obstructive effect Effects 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 206010050389 Cerebral ataxia Diseases 0.000 claims description 5
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 206010028343 Muscle tone abnormalities Diseases 0.000 claims description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 206010036631 Presenile dementia Diseases 0.000 claims description 5
- 206010049644 Williams syndrome Diseases 0.000 claims description 5
- 230000006399 behavior Effects 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 201000009032 substance abuse Diseases 0.000 claims description 5
- 231100000736 substance abuse Toxicity 0.000 claims description 5
- 230000000946 synaptic effect Effects 0.000 claims description 5
- 230000003956 synaptic plasticity Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010002329 Aneurysm Diseases 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 208000021910 Cerebral Arterial disease Diseases 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000004483 Dyspareunia Diseases 0.000 claims description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 4
- 208000000289 Esophageal Achalasia Diseases 0.000 claims description 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010030136 Oesophageal achalasia Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000028361 Penetrating Head injury Diseases 0.000 claims description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 201000000621 achalasia Diseases 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 230000008694 endothelial dysfunction Effects 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 230000002123 temporal effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 230000001732 thrombotic effect Effects 0.000 claims description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 208000010482 CADASIL Diseases 0.000 claims description 3
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 3
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims description 3
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 claims description 3
- 208000024254 Delusional disease Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 239000008896 Opium Substances 0.000 claims description 3
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 3
- 208000011142 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000024825 childhood disintegrative disease Diseases 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 230000036651 mood Effects 0.000 claims description 3
- 229960001027 opium Drugs 0.000 claims description 3
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010002153 Anal fissure Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010012559 Developmental delay Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 208000009531 Fissure in Ano Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010020852 Hypertonia Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010021133 Hypoventilation Diseases 0.000 claims description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000011682 Mitral valve disease Diseases 0.000 claims description 2
- 206010028342 Muscle tone abnormal Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 206010061340 Peripheral embolism Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims description 2
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims description 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims description 2
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims description 2
- 208000032159 Vaginal inflammation Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 208000013228 adenopathy Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims description 2
- 206010002906 aortic stenosis Diseases 0.000 claims description 2
- 208000008784 apnea Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000037849 arterial hypertension Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 239000003633 blood substitute Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010007625 cardiogenic shock Diseases 0.000 claims description 2
- 230000020411 cell activation Effects 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 230000009852 coagulant defect Effects 0.000 claims description 2
- 208000028831 congenital heart disease Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 230000003205 diastolic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000002545 drug psychosis Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 230000001856 erectile effect Effects 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 208000001288 gastroparesis Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000018875 hypoxemia Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000030175 lameness Diseases 0.000 claims description 2
- 230000007775 late Effects 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001231 mediastinitis Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 2
- 210000001147 pulmonary artery Anatomy 0.000 claims description 2
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000014038 regulation of leukocyte activation Effects 0.000 claims description 2
- 230000010451 regulation of platelet aggregation Effects 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 208000015658 resistant hypertension Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 2
- 230000007958 sleep Effects 0.000 claims description 2
- 230000004622 sleep time Effects 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 230000002739 subcortical effect Effects 0.000 claims description 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000009424 thromboembolic effect Effects 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 0 Cc1n[n](cc(C)nc2[*+])c2n1 Chemical compound Cc1n[n](cc(C)nc2[*+])c2n1 0.000 description 18
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- GTKNNCQKFKGSHR-UHFFFAOYSA-N FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)(F)F Chemical compound FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)(F)F GTKNNCQKFKGSHR-UHFFFAOYSA-N 0.000 description 2
- QZQWREBFEWGITD-UHFFFAOYSA-N FC(c1n[nH]c(-c2c[n]3ncnc3c(Cc(cccc3)c3F)n2)n1)(F)F Chemical compound FC(c1n[nH]c(-c2c[n]3ncnc3c(Cc(cccc3)c3F)n2)n1)(F)F QZQWREBFEWGITD-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- YDFOJEXFGLECFW-VURMDHGXSA-N C/C(/N)=C(\C)/N1N=C(C)N=C(C)C1=C Chemical compound C/C(/N)=C(\C)/N1N=C(C)N=C(C)C1=C YDFOJEXFGLECFW-VURMDHGXSA-N 0.000 description 1
- RJZBGYHRNPBQGB-UHFFFAOYSA-O C/C(/NCC(F)(F)F)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] Chemical compound C/C(/NCC(F)(F)F)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] RJZBGYHRNPBQGB-UHFFFAOYSA-O 0.000 description 1
- JIYAYDSZBGRNBT-UHFFFAOYSA-O C/C(/NCCC(F)(F)F)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] Chemical compound C/C(/NCCC(F)(F)F)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] JIYAYDSZBGRNBT-UHFFFAOYSA-O 0.000 description 1
- JRLUANYLXXGRSC-UHFFFAOYSA-N C/C(/NCc1cccc(F)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=N Chemical compound C/C(/NCc1cccc(F)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=N JRLUANYLXXGRSC-UHFFFAOYSA-N 0.000 description 1
- PLYAUYSZKSMVLP-UHFFFAOYSA-O C/C(/NCc1n[o]c(C)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] Chemical compound C/C(/NCc1n[o]c(C)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] PLYAUYSZKSMVLP-UHFFFAOYSA-O 0.000 description 1
- DYAFQLPJKVMJDF-LUAWRHEFSA-N CC(/N=C(/C(C)=NC(C)=C1)\N1N)=C Chemical compound CC(/N=C(/C(C)=NC(C)=C1)\N1N)=C DYAFQLPJKVMJDF-LUAWRHEFSA-N 0.000 description 1
- GZANVCVUIMMLPI-UHFFFAOYSA-N CC(C)(C)C(C[n]1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)nc1C)=O Chemical compound CC(C)(C)C(C[n]1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)nc1C)=O GZANVCVUIMMLPI-UHFFFAOYSA-N 0.000 description 1
- KAVWRKIPJAUPNH-UHFFFAOYSA-O CC(N=C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)[NH2+]CC(F)(F)F)=N Chemical compound CC(N=C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)[NH2+]CC(F)(F)F)=N KAVWRKIPJAUPNH-UHFFFAOYSA-O 0.000 description 1
- JXSXWPCTRNLHOL-UITAMQMPSA-N CCC(C)/N=C\c1nc(C)n[nH]1 Chemical compound CCC(C)/N=C\c1nc(C)n[nH]1 JXSXWPCTRNLHOL-UITAMQMPSA-N 0.000 description 1
- YYNAOPKXWYXRCV-UHFFFAOYSA-O CCCCN/C(/C)=N\C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] Chemical compound CCCCN/C(/C)=N\C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] YYNAOPKXWYXRCV-UHFFFAOYSA-O 0.000 description 1
- MOMVGZOGCGVNET-UHFFFAOYSA-N CCc1c(C=C)c2c(C)nc(C)nc2[n]1C Chemical compound CCc1c(C=C)c2c(C)nc(C)nc2[n]1C MOMVGZOGCGVNET-UHFFFAOYSA-N 0.000 description 1
- SMZGWCXWGGVUFW-UHFFFAOYSA-N CCc1nc(C)nc2nc(C)n[n]12 Chemical compound CCc1nc(C)nc2nc(C)n[n]12 SMZGWCXWGGVUFW-UHFFFAOYSA-N 0.000 description 1
- LSWAKDZKMGFLJI-UHFFFAOYSA-O CN(C)C(N=C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)[NH3+])=N Chemical compound CN(C)C(N=C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)[NH3+])=N LSWAKDZKMGFLJI-UHFFFAOYSA-O 0.000 description 1
- IOJMULZYBCYKSK-OUPQRBNQSA-N CN/C=C\N(/C=C(/C(/N)=N/C(C(F)(F)F)=N)\N=C)F Chemical compound CN/C=C\N(/C=C(/C(/N)=N/C(C(F)(F)F)=N)\N=C)F IOJMULZYBCYKSK-OUPQRBNQSA-N 0.000 description 1
- LKMPSTAPAGVFSJ-UHFFFAOYSA-N Cc(nc1C)c(c(C)n2)[n]1nc2I Chemical compound Cc(nc1C)c(c(C)n2)[n]1nc2I LKMPSTAPAGVFSJ-UHFFFAOYSA-N 0.000 description 1
- XKDNVITXZLITAI-UHFFFAOYSA-N Cc(nc1C)c2[n]1c(C)nc(N)c2 Chemical compound Cc(nc1C)c2[n]1c(C)nc(N)c2 XKDNVITXZLITAI-UHFFFAOYSA-N 0.000 description 1
- NXCMWGSECDNUCI-UHFFFAOYSA-N Cc(nc1N)cc(N=N)c1NC Chemical compound Cc(nc1N)cc(N=N)c1NC NXCMWGSECDNUCI-UHFFFAOYSA-N 0.000 description 1
- JJSYHKJWEMGYMR-UHFFFAOYSA-N Cc1c(C)[n]2c(C)nccc2c1C Chemical compound Cc1c(C)[n]2c(C)nccc2c1C JJSYHKJWEMGYMR-UHFFFAOYSA-N 0.000 description 1
- VZIRZPDQOWCEMJ-UHFFFAOYSA-N Cc1c(C)nc2[n]1cc(C)nc2C Chemical compound Cc1c(C)nc2[n]1cc(C)nc2C VZIRZPDQOWCEMJ-UHFFFAOYSA-N 0.000 description 1
- LCKXPGXBYMPVQK-UHFFFAOYSA-O Cc1c(C)nc2[n]1cc(N)nc2[NH3+] Chemical compound Cc1c(C)nc2[n]1cc(N)nc2[NH3+] LCKXPGXBYMPVQK-UHFFFAOYSA-O 0.000 description 1
- RUQNBFFURYTNPL-UHFFFAOYSA-N Cc1c(c(I)nc(C)c2)[n]2c(C)n1 Chemical compound Cc1c(c(I)nc(C)c2)[n]2c(C)n1 RUQNBFFURYTNPL-UHFFFAOYSA-N 0.000 description 1
- CPIZXNUJYOUWOI-UHFFFAOYSA-N Cc1c2[n](C)nnc2nc(C)n1 Chemical compound Cc1c2[n](C)nnc2nc(C)n1 CPIZXNUJYOUWOI-UHFFFAOYSA-N 0.000 description 1
- GCENBMJRCQSOAB-UHFFFAOYSA-N Cc1c2nc(C)nc(C)[n]2c(C)n1 Chemical compound Cc1c2nc(C)nc(C)[n]2c(C)n1 GCENBMJRCQSOAB-UHFFFAOYSA-N 0.000 description 1
- DVUHAYBOPNCNKO-UHFFFAOYSA-N Cc1c2nc(N)nc(C)[n]2nc1C Chemical compound Cc1c2nc(N)nc(C)[n]2nc1C DVUHAYBOPNCNKO-UHFFFAOYSA-N 0.000 description 1
- PZJQTLDVKSCUCU-UHFFFAOYSA-N Cc1c2nn[n](C)c2nc(I)n1 Chemical compound Cc1c2nn[n](C)c2nc(I)n1 PZJQTLDVKSCUCU-UHFFFAOYSA-N 0.000 description 1
- HCGYASUZOVTXDY-UHFFFAOYSA-N Cc1c[n](cc(-c2nc(C(F)(F)F)n[nH]2)nc2Cc(cccc3)c3F)c2n1 Chemical compound Cc1c[n](cc(-c2nc(C(F)(F)F)n[nH]2)nc2Cc(cccc3)c3F)c2n1 HCGYASUZOVTXDY-UHFFFAOYSA-N 0.000 description 1
- QDVLAUXUPDLIKM-UHFFFAOYSA-N Cc1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 Chemical compound Cc1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 QDVLAUXUPDLIKM-UHFFFAOYSA-N 0.000 description 1
- IBEFDXFNHMQZCO-UHFFFAOYSA-N Cc1n[n](Cc(cc2)ccc2F)c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 Chemical compound Cc1n[n](Cc(cc2)ccc2F)c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 IBEFDXFNHMQZCO-UHFFFAOYSA-N 0.000 description 1
- LWYUOQZUHKRGFU-UHFFFAOYSA-N Cc1n[n]2c(C)nc(N)cc2n1 Chemical compound Cc1n[n]2c(C)nc(N)cc2n1 LWYUOQZUHKRGFU-UHFFFAOYSA-N 0.000 description 1
- SSWHNIUYSAYAJC-UHFFFAOYSA-N Cc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1CCCCF Chemical compound Cc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1CCCCF SSWHNIUYSAYAJC-UHFFFAOYSA-N 0.000 description 1
- DKVSXAYWNNQMDN-UHFFFAOYSA-N Cc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1Cc(cc1)ccc1F Chemical compound Cc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1Cc(cc1)ccc1F DKVSXAYWNNQMDN-UHFFFAOYSA-N 0.000 description 1
- QPYMLEIEQUIMPO-UHFFFAOYSA-N Cc1nnc2[n]1cc(C)nc2C Chemical compound Cc1nnc2[n]1cc(C)nc2C QPYMLEIEQUIMPO-UHFFFAOYSA-N 0.000 description 1
- WPDVHETVPOCACL-UHFFFAOYSA-N FC(C(F)(F)F)(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)F Chemical compound FC(C(F)(F)F)(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)F WPDVHETVPOCACL-UHFFFAOYSA-N 0.000 description 1
- MTVMYCYALISMMW-UHFFFAOYSA-N FC(C1)(C1c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)F Chemical compound FC(C1)(C1c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1)F MTVMYCYALISMMW-UHFFFAOYSA-N 0.000 description 1
- LKKUCJGDRVNNOI-UHFFFAOYSA-N FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3Cl)n1)(F)F Chemical compound FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3Cl)n1)(F)F LKKUCJGDRVNNOI-UHFFFAOYSA-N 0.000 description 1
- IAKPTHYTPQBDLV-UHFFFAOYSA-N FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3I)n1)(F)F Chemical compound FC(c1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3I)n1)(F)F IAKPTHYTPQBDLV-UHFFFAOYSA-N 0.000 description 1
- QPBUYZPOBSFTOD-UHFFFAOYSA-N FC(c1n[nH]c(-c(nc2Cc3cccc(F)c3)c[n]3c2ncc3)n1)(F)F Chemical compound FC(c1n[nH]c(-c(nc2Cc3cccc(F)c3)c[n]3c2ncc3)n1)(F)F QPBUYZPOBSFTOD-UHFFFAOYSA-N 0.000 description 1
- QXRJBEDYDXPIPO-UHFFFAOYSA-N FC(c1n[nH]c(-c2c[n]3ncnc3c(Cc3cccc(F)c3)n2)n1)(F)F Chemical compound FC(c1n[nH]c(-c2c[n]3ncnc3c(Cc3cccc(F)c3)n2)n1)(F)F QXRJBEDYDXPIPO-UHFFFAOYSA-N 0.000 description 1
- JXLXCAYFSRPHLB-UHFFFAOYSA-N Fc1c(Cc2nc(-c3nc(-[n]4cncc4)n[nH]3)c[n]3c2ncc3)cccc1 Chemical compound Fc1c(Cc2nc(-c3nc(-[n]4cncc4)n[nH]3)c[n]3c2ncc3)cccc1 JXLXCAYFSRPHLB-UHFFFAOYSA-N 0.000 description 1
- QJCHFYPTVVBWKU-UHFFFAOYSA-N Fc1c(Cc2nc(-c3nc(Cl)n[nH]3)c[n]3c2ncc3)cccc1 Chemical compound Fc1c(Cc2nc(-c3nc(Cl)n[nH]3)c[n]3c2ncc3)cccc1 QJCHFYPTVVBWKU-UHFFFAOYSA-N 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- UFIYQOZNWLEOAT-UHFFFAOYSA-N N#Cc1cnc2[n]1cc(-c1nc(C(F)(F)F)c[nH]1)nc2Cc(cccc1)c1F Chemical compound N#Cc1cnc2[n]1cc(-c1nc(C(F)(F)F)c[nH]1)nc2Cc(cccc1)c1F UFIYQOZNWLEOAT-UHFFFAOYSA-N 0.000 description 1
- BPDIGRXDZUFXQS-UHFFFAOYSA-O N/C(/C(N=C1Cc(cccc2)c2F)=CN(C=N)C1=[NH2+])=N\C(C(F)(F)F)=N Chemical compound N/C(/C(N=C1Cc(cccc2)c2F)=CN(C=N)C1=[NH2+])=N\C(C(F)(F)F)=N BPDIGRXDZUFXQS-UHFFFAOYSA-O 0.000 description 1
- SZUXXROAQBYKOH-UHFFFAOYSA-O N/C(/NCc1cccc(F)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] Chemical compound N/C(/NCc1cccc(F)c1)=N/C(c(nc1Cc(cccc2)c2F)c[n]2c1ncc2)=[NH2+] SZUXXROAQBYKOH-UHFFFAOYSA-O 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- FKDJEFXZEYPIEG-UHFFFAOYSA-N Nc1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 Chemical compound Nc1n[nH]c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 FKDJEFXZEYPIEG-UHFFFAOYSA-N 0.000 description 1
- GGUHGFJEKNVEHE-UHFFFAOYSA-N Nc1n[n](CC(F)(F)F)c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 Chemical compound Nc1n[n](CC(F)(F)F)c(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n1 GGUHGFJEKNVEHE-UHFFFAOYSA-N 0.000 description 1
- DQOKEHHZWXLADL-UHFFFAOYSA-N Nc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1CC(F)(F)F Chemical compound Nc1nc(-c(nc2Cc(cccc3)c3F)c[n]3c2ncc3)n[n]1CC(F)(F)F DQOKEHHZWXLADL-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- -1 ethyl chain compound Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022050708A JP7628096B2 (ja) | 2016-09-02 | 2022-03-25 | 縮合二環式ｓｇｃ刺激剤 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382942P | 2016-09-02 | 2016-09-02 | |
| US62/382,942 | 2016-09-02 | ||
| US201662423445P | 2016-11-17 | 2016-11-17 | |
| US62/423,445 | 2016-11-17 | ||
| US201762468598P | 2017-03-08 | 2017-03-08 | |
| US62/468,598 | 2017-03-08 | ||
| US201762482486P | 2017-04-06 | 2017-04-06 | |
| US62/482,486 | 2017-04-06 | ||
| PCT/US2017/049834 WO2018045276A1 (en) | 2016-09-02 | 2017-09-01 | Fused bicyclic sgc stimulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022050708A Division JP7628096B2 (ja) | 2016-09-02 | 2022-03-25 | 縮合二環式ｓｇｃ刺激剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526582A JP2019526582A (ja) | 2019-09-19 |
| JP2019526582A5 true JP2019526582A5 (enExample) | 2020-10-15 |
| JP7050759B2 JP7050759B2 (ja) | 2022-04-08 |
Family
ID=59887396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512205A Active JP7050759B2 (ja) | 2016-09-02 | 2017-09-01 | 縮合二環式ｓｇｃ刺激剤 |
| JP2022050708A Active JP7628096B2 (ja) | 2016-09-02 | 2022-03-25 | 縮合二環式ｓｇｃ刺激剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022050708A Active JP7628096B2 (ja) | 2016-09-02 | 2022-03-25 | 縮合二環式ｓｇｃ刺激剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US10472363B2 (enExample) |
| EP (2) | EP3507291B1 (enExample) |
| JP (2) | JP7050759B2 (enExample) |
| KR (2) | KR102568384B1 (enExample) |
| CN (2) | CN117105939B (enExample) |
| AU (2) | AU2017321810B2 (enExample) |
| CA (1) | CA3035210A1 (enExample) |
| CL (1) | CL2019000486A1 (enExample) |
| CO (1) | CO2019001760A2 (enExample) |
| CR (2) | CR20220309A (enExample) |
| CY (1) | CY1124612T1 (enExample) |
| DK (1) | DK3507291T3 (enExample) |
| ES (2) | ES2885003T3 (enExample) |
| HR (1) | HRP20211355T1 (enExample) |
| HU (1) | HUE056051T2 (enExample) |
| IL (2) | IL292968B2 (enExample) |
| LT (1) | LT3507291T (enExample) |
| MA (1) | MA53999A (enExample) |
| MX (3) | MX394958B (enExample) |
| MY (1) | MY199759A (enExample) |
| PE (1) | PE20190607A1 (enExample) |
| PH (1) | PH12019500461B1 (enExample) |
| PL (1) | PL3507291T3 (enExample) |
| PT (1) | PT3507291T (enExample) |
| RS (1) | RS62256B1 (enExample) |
| SG (1) | SG11201901729YA (enExample) |
| SI (1) | SI3507291T1 (enExample) |
| TW (2) | TWI813078B (enExample) |
| WO (1) | WO2018045276A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100467946B1 (ko) * | 1997-01-24 | 2005-01-24 | 로무 가부시키가이샤 | 반도체 칩의 제조방법 |
| MX2017003518A (es) * | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| CA3015172A1 (en) | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
| MY199759A (en) | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
| SG10202104865UA (en) * | 2016-11-08 | 2021-06-29 | Cyclerion Therapeutics Inc | Treatment of cns diseases with sgc stimulators |
| WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| AU2019231721B2 (en) | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Process for preparing soluble guanylate cyclase stimulators |
| AU2019231724B2 (en) * | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Crystalline forms of an sGC stimulator |
| WO2019211081A1 (en) * | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| SG11202100092QA (en) | 2018-07-11 | 2021-02-25 | Cyclerion Therapeutics Inc | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
| GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| AU2019389263B2 (en) * | 2018-11-28 | 2025-05-22 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN110305125B (zh) * | 2019-06-06 | 2021-09-03 | 山东新华制药股份有限公司 | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 |
| CN114980899A (zh) * | 2019-11-26 | 2022-08-30 | 普拉西斯精密医药公司 | 离子通道调节剂 |
| WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
| TW202228697A (zh) | 2020-10-13 | 2022-08-01 | 美商賽克瑞恩醫療公司 | 以CNS穿透性sGC刺激劑治療認知損傷 |
| CN117957228A (zh) * | 2021-04-20 | 2024-04-30 | 帝善多制药公司 | sGC刺激剂 |
| AU2022261862A1 (en) | 2021-04-20 | 2023-11-30 | Tisento Therapeutics Inc. | Sgc stimulators |
| TW202308634A (zh) | 2021-04-20 | 2023-03-01 | 美商賽克瑞恩醫療公司 | 使用sGC刺激劑之CNS疾病治療 |
| US20240099979A1 (en) * | 2021-06-01 | 2024-03-28 | Privo Technologies, Inc. | Enhanced two-stage microparticle-based localized therapeutic delivery system |
| WO2023148203A1 (en) | 2022-02-01 | 2023-08-10 | Charité - Universitätsmedizin Berlin | A soluble guanylat cyclase activator for treating chronic vascular dysfunction |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| EP4605080A1 (en) | 2022-10-18 | 2025-08-27 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
| CN119285629A (zh) * | 2024-09-03 | 2025-01-10 | 中南大学 | 5-[1,2,4-噁二唑]-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 |
| CN119185590B (zh) * | 2024-11-28 | 2025-02-25 | 华润双鹤利民药业（济南）有限公司 | 羟丙基-β-环糊精在制备维立西呱固体制剂中的应用、固体制剂及制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| PL199236B1 (pl) | 1998-07-08 | 2008-08-29 | Sanofi Aventis Deutschland | N-Aryloamidy kwasów sulfonyloaminokarboksylowych podstawionych siarką, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie N-aryloamidów kwasów sulfonyloaminokarboksylowych podstawionych siarką |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| WO2003059346A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| MXPA06001506A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa. |
| CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| WO2009094242A1 (en) | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
| WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| EP2401265B1 (en) | 2009-02-26 | 2016-09-14 | Merck Sharp & Dohme Corp. | Derivatives of 1-pyri(mid)in-2-yl-pyrazole-4-carboxylic acid which are useful for therapy or prophylaxis of cardiovascular diseases |
| HRP20150345T1 (hr) | 2009-09-24 | 2015-05-08 | F. Hoffmann-La Roche Ag | Derivati imidazopiridina ili imidazopirimidina kao inhibitori fosfodiesteraze 10a |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EA026692B1 (ru) | 2010-06-30 | 2017-05-31 | Айронвуд Фармасьютикелз, Инк. | Стимуляторы sgc |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2012064559A1 (en) * | 2010-11-09 | 2012-05-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| WO2014047111A1 (en) * | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| RS63108B1 (sr) * | 2013-03-15 | 2022-04-29 | Cyclerion Therapeutics Inc | Sgc stimulatori |
| US20160311826A1 (en) | 2013-12-11 | 2016-10-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| MX2017003518A (es) * | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| EP3227286B1 (de) * | 2014-12-02 | 2018-12-26 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
| EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| WO2016191335A1 (en) | 2015-05-28 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| WO2017002120A1 (en) | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
| WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
| TN2018000198A1 (en) | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| GB201614934D0 (en) | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| MY199759A (en) * | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
| TWI886480B (zh) | 2017-04-06 | 2025-06-11 | 美商富曼西公司 | 殺真菌之噁二唑 |
| EP3606922A4 (en) | 2017-04-06 | 2021-03-03 | Hangzhou Dac Biotech Co., Ltd | CONJUGATION OF A CYTOSTATIC WITH BIS CONNECTION |
-
2017
- 2017-09-01 MY MYPI2019001096A patent/MY199759A/en unknown
- 2017-09-01 ES ES17768311T patent/ES2885003T3/es active Active
- 2017-09-01 EP EP17768311.7A patent/EP3507291B1/en active Active
- 2017-09-01 MX MX2021007580A patent/MX394958B/es unknown
- 2017-09-01 CN CN202310684903.5A patent/CN117105939B/zh active Active
- 2017-09-01 CN CN201780059390.1A patent/CN109790167B/zh active Active
- 2017-09-01 PT PT177683117T patent/PT3507291T/pt unknown
- 2017-09-01 PE PE2019000448A patent/PE20190607A1/es unknown
- 2017-09-01 HR HRP20211355TT patent/HRP20211355T1/hr unknown
- 2017-09-01 PL PL17768311T patent/PL3507291T3/pl unknown
- 2017-09-01 CA CA3035210A patent/CA3035210A1/en active Pending
- 2017-09-01 US US15/693,758 patent/US10472363B2/en active Active
- 2017-09-01 CR CR20220309A patent/CR20220309A/es unknown
- 2017-09-01 SI SI201730889T patent/SI3507291T1/sl unknown
- 2017-09-01 MX MX2019002313A patent/MX383782B/es unknown
- 2017-09-01 TW TW110143580A patent/TWI813078B/zh active
- 2017-09-01 KR KR1020197008522A patent/KR102568384B1/ko active Active
- 2017-09-01 MA MA053999A patent/MA53999A/fr unknown
- 2017-09-01 LT LTEP17768311.7T patent/LT3507291T/lt unknown
- 2017-09-01 PH PH1/2019/500461A patent/PH12019500461B1/en unknown
- 2017-09-01 KR KR1020237027632A patent/KR102854313B1/ko active Active
- 2017-09-01 TW TW106129952A patent/TWI750218B/zh active
- 2017-09-01 AU AU2017321810A patent/AU2017321810B2/en active Active
- 2017-09-01 HU HUE17768311A patent/HUE056051T2/hu unknown
- 2017-09-01 RS RS20211055A patent/RS62256B1/sr unknown
- 2017-09-01 SG SG11201901729YA patent/SG11201901729YA/en unknown
- 2017-09-01 EP EP21167805.7A patent/EP3872080B1/en active Active
- 2017-09-01 DK DK17768311.7T patent/DK3507291T3/da active
- 2017-09-01 WO PCT/US2017/049834 patent/WO2018045276A1/en not_active Ceased
- 2017-09-01 IL IL292968A patent/IL292968B2/en unknown
- 2017-09-01 CR CR20190101A patent/CR20190101A/es unknown
- 2017-09-01 IL IL264955A patent/IL264955B/en unknown
- 2017-09-01 ES ES21167805T patent/ES2957159T3/es active Active
- 2017-09-01 JP JP2019512205A patent/JP7050759B2/ja active Active
-
2019
- 2019-02-12 US US16/273,557 patent/US10858363B2/en active Active
- 2019-02-22 CL CL2019000486A patent/CL2019000486A1/es unknown
- 2019-02-26 MX MX2021007579A patent/MX2021007579A/es unknown
- 2019-02-26 CO CONC2019/0001760A patent/CO2019001760A2/es unknown
-
2020
- 2020-12-04 US US17/112,351 patent/US20210087198A1/en not_active Abandoned
-
2021
- 2021-08-24 CY CY20211100756T patent/CY1124612T1/el unknown
- 2021-09-27 US US17/485,892 patent/US11731977B2/en active Active
-
2022
- 2022-03-25 JP JP2022050708A patent/JP7628096B2/ja active Active
- 2022-03-30 AU AU2022202167A patent/AU2022202167B2/en active Active
-
2025
- 2025-01-29 US US19/040,267 patent/US20250326761A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526582A5 (enExample) | ||
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| DE60124577T2 (de) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
| JP6043935B2 (ja) | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 | |
| JP3335362B2 (ja) | キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト | |
| EP2802589B1 (en) | Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders | |
| JP2020506899A5 (enExample) | ||
| TWI439464B (zh) | 二胺衍生物之製造方法 | |
| JP2016517432A5 (enExample) | ||
| JPH06501941A (ja) | アリールピリダジノン | |
| TW201326127A (zh) | 新穎菸鹼醯胺衍生物或其鹽 | |
| JPS59501409A (ja) | ピリドン化合物 | |
| JP2016505063A (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| JP2024153885A (ja) | 新規なピラゾール誘導体 | |
| JP2019534310A (ja) | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 | |
| TW201619133A (zh) | 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物 | |
| JP5274012B2 (ja) | ピリドンカルボン酸抗菌薬の調製 | |
| JP7025555B2 (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| AU2019300106A1 (en) | Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating a RNA virus infection | |
| JP2010517958A (ja) | ＰＤＥ５インヒビターとして有用な６−ベンジル−２，３，４，７−テトラヒドロ−インドロ［２，３−ｃ］キノリン化合物 | |
| JP2660016B2 (ja) | 治療用薬剤 | |
| JP6667507B2 (ja) | ピラゾロ［３，４−ｃ］ピリジン誘導体 | |
| JP6007339B2 (ja) | イミダゾピリジン誘導体 | |
| CN112996513B (zh) | 新颖哒嗪 | |
| CN116514728A (zh) | 一种喹唑啉衍生物及其用途 |